RxDoctor Payments Data

Erin Glassman, PA

Physician Assistant · Langhorne, PANPI 1053660761

Payments from drug & device makers

$3,475in general payments, 2019–2025

Across 126 payments — averaging $27.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AbbVie$435
  • Sumitomo Pharma America, Inc.$390
  • Astellas Pharma US Inc$140
  • Endo Pharmaceuticals Inc.$137
  • Convatec Inc.$134
  • plus $1K from 22 others
$210in research payments, 2019–2025

Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$210

What the payments were for

  • Consulting fees$1053%
  • Travel & lodging$1605%
  • Food & beverage$3,09289%
  • Education$1183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,475 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$57,488
Medicare patients
276
Services billed
1,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron146$117,745
MyrbetriqMirabegron116$77,805
EstringEstradiol18$9,281
Estradiol141$8,257
Mirabegron ErMirabegron15$7,911
Methenamine Hippurate55$3,736
Trospium Chloride ErTrospium Chloride17$3,199
YuvafemEstradiol17$1,942
Trospium Chloride38$1,198
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst63$720
Solifenacin Succinate28$484
NitrofurantoinNitrofurantoin Macrocrystal30$479
Oxybutynin Chloride ErOxybutynin Chloride16$410
Tamsulosin Hcl20$363
CefuroximeCefuroxime Axetil29$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$390$117,745146 claims
Astellas Pharma US IncMyrbetriq$140$77,805116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →